Literature DB >> 28888781

Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating β2-integrin-dependent function in human eosinophils.

Daniela J Carroll1, Jeremy A O'Sullivan1, David B Nix2, Yun Cao1, Michael Tiemeyer2, Bruce S Bochner3.   

Abstract

BACKGROUND: Siglec-8 is a CD33 subfamily cell-surface receptor selectively expressed on human eosinophils. After cytokine priming, Siglec-8 mAb or glycan ligand binding causes eosinophil apoptosis associated with reactive oxygen species (ROS) production. Most CD33-related Siglecs function as inhibitory receptors, but the ability of Siglec-8 to stimulate eosinophil ROS production and apoptosis suggests that Siglec-8 might instead function as an activating receptor.
OBJECTIVE: We sought to determine the role of IL-5 priming and identify the signaling molecules involved in Siglec-8 function for human eosinophils.
METHODS: We used an mAb and/or a multimeric synthetic sulfated sialoglycan ligand recognizing Siglec-8 in combination with integrin blocking antibodies, pharmacologic inhibitors, phosphoproteomics, and Western blot analysis to define the necessity of various proteins involved in Siglec-8 function for human eosinophils.
RESULTS: Cytokine priming was required to elicit the unanticipated finding that Siglec-8 engagement promotes rapid β2-integrin-dependent eosinophil adhesion. Also novel was the finding that this adhesion was necessary for subsequent ROS production and apoptosis. Siglec-8-mediated ROS was generated through reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation because pretreatment of eosinophils with catalase (an extracellular superoxide scavenger) or NSC 23766 (a Rac GTPase inhibitor) completely inhibited Siglec-8-mediated eosinophil apoptosis. Finally, engagement of Siglec-8 on IL-5-primed eosinophils resulted in increased phosphorylation of Akt, p38, and c-Jun N-terminal kinase 1 that was also β2-integrin dependent; pharmacologic inhibition of these kinases completely prevented Siglec-8-mediated eosinophil apoptosis.
CONCLUSIONS: These data demonstrate that Siglec-8 functions uniquely as an activating receptor on IL-5-primed eosinophils through a novel pathway involving regulation of β2-integrin-dependent adhesion, NADPH oxidase, and a subset of protein kinases.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akt; Eosinophil; Siglec-8; apoptosis; c-Jun N-terminal kinase (JNK); p38; phosphoproteomics; reduced nicotinamide adenine dinucleotide phosphate oxidase (NADPH); β(2)-integrin

Mesh:

Substances:

Year:  2017        PMID: 28888781      PMCID: PMC5839929          DOI: 10.1016/j.jaci.2017.08.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  62 in total

1.  Mechanism of Siglec-8-induced human eosinophil apoptosis: role of caspases and mitochondrial injury.

Authors:  Esra Nutku; Sherry A Hudson; Bruce S Bochner
Journal:  Biochem Biophys Res Commun       Date:  2005-10-28       Impact factor: 3.575

2.  Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily.

Authors:  H Floyd; J Ni; A L Cornish; Z Zeng; D Liu; K C Carter; J Steel; P R Crocker
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

3.  'Outside-in' signalling mechanisms underlying CD11b/CD18-mediated NADPH oxidase activation in human adherent blood eosinophils.

Authors:  O T Lynch; M A Giembycz; P J Barnes; P G Hellewell; M A Lindsay
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  Anti-IL-5 attenuates activation and surface density of β(2) -integrins on circulating eosinophils after segmental antigen challenge.

Authors:  M W Johansson; K A Gunderson; E A B Kelly; L C Denlinger; N N Jarjour; D F Mosher
Journal:  Clin Exp Allergy       Date:  2013-03       Impact factor: 5.018

Review 5.  Reactive oxygen species-induced activation of the MAP kinase signaling pathways.

Authors:  James A McCubrey; Michelle M Lahair; Richard A Franklin
Journal:  Antioxid Redox Signal       Date:  2006 Sep-Oct       Impact factor: 8.401

6.  Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters.

Authors:  T Angata; R Hingorani; N M Varki; A Varki
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

7.  Role of stress-activated mitogen-activated protein kinase (p38) in beta 2-integrin-dependent neutrophil adhesion and the adhesion-dependent oxidative burst.

Authors:  P A Detmers; D Zhou; E Polizzi; R Thieringer; W A Hanlon; S Vaidya; V Bansal
Journal:  J Immunol       Date:  1998-08-15       Impact factor: 5.422

8.  The Peripheral Blood Eosinophil Proteome.

Authors:  Emily M Wilkerson; Mats W Johansson; Alexander S Hebert; Michael S Westphall; Sameer K Mathur; Nizar N Jarjour; Elizabeth A Schwantes; Deane F Mosher; Joshua J Coon
Journal:  J Proteome Res       Date:  2016-04-01       Impact factor: 4.466

9.  α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin.

Authors:  Mats W Johansson; Douglas S Annis; Deane F Mosher
Journal:  Am J Respir Cell Mol Biol       Date:  2013-04       Impact factor: 6.914

10.  Siglec-E promotes β2-integrin-dependent NADPH oxidase activation to suppress neutrophil recruitment to the lung.

Authors:  Sarah J McMillan; Ritu S Sharma; Hannah E Richards; Vikas Hegde; Paul R Crocker
Journal:  J Biol Chem       Date:  2014-06-03       Impact factor: 5.157

View more
  19 in total

1.  Frontline Science: Superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: Mechanisms and pitfalls.

Authors:  Eva Knuplez; Rebecca Krier-Burris; Yun Cao; Gunther Marsche; Jeremy O'Sullivan; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-03-05       Impact factor: 4.962

2.  Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps.

Authors:  Charlotte Marx; Julia Novotny; Danby Salbeck; Katie R Zellner; Leo Nicolai; Kami Pekayvaz; Badr Kilani; Sven Stockhausen; Niklas Bürgener; Danny Kupka; Thomas J Stocker; Ludwig T Weckbach; Joachim Pircher; Markus Moser; Michael Joner; Walter Desmet; Tom Adriaenssens; Franz-Josef Neumann; Anthony H Gerschlick; Jurrien M Ten Berg; Michael Lorenz; Konstantin Stark
Journal:  Blood       Date:  2019-11-21       Impact factor: 22.113

Review 3.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

4.  Siglec-7 on peripheral blood eosinophils: Surface expression and function.

Authors:  Fanny Legrand; Nadine Landolina; Ilan Zaffran; Robert O Emeh; Elizabeth Chen; Amy D Klion; Francesca Levi-Schaffer
Journal:  Allergy       Date:  2019-02-26       Impact factor: 13.146

5.  Characterization of Siglec-8 Expression on Lavage Cells after Segmental Lung Allergen Challenge.

Authors:  Mats W Johansson; Elizabeth A Kelly; Christopher L Nguyen; Nizar N Jarjour; Bruce S Bochner
Journal:  Int Arch Allergy Immunol       Date:  2018-06-07       Impact factor: 2.749

Review 6.  Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).

Authors:  Paneez Khoury; Praveen Akuthota; Steven J Ackerman; Joseph R Arron; Bruce S Bochner; Margaret H Collins; Jean-Emmanuel Kahn; Patricia C Fulkerson; Gerald J Gleich; Rashmi Gopal-Srivastava; Elizabeth A Jacobsen; Kristen M Leiferman; Levi-Schaffer Francesca; Sameer K Mathur; Michael Minnicozzi; Calman Prussin; Marc E Rothenberg; Florence Roufosse; Kathleen Sable; Dagmar Simon; Hans-Uwe Simon; Lisa A Spencer; Jonathan Steinfeld; Andrew J Wardlaw; Michael E Wechsler; Peter F Weller; Amy D Klion
Journal:  J Leukoc Biol       Date:  2018-04-19       Impact factor: 4.962

7.  Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.

Authors:  Fanny Legrand; Yun Cao; Joshua B Wechsler; Xiang Zhu; Nives Zimmermann; Shakuntala Rampertaap; Joseph Monsale; Kimberly Romito; Bradford A Youngblood; Emily C Brock; Michelle A Makiya; Nenad Tomasevic; Christopher Bebbington; Irina Maric; Dean D Metcalfe; Bruce S Bochner; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2018-12-10       Impact factor: 10.793

8.  A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells.

Authors:  Corwin M Nycholat; Shiteng Duan; Eva Knuplez; Charli Worth; Mila Elich; Anzhi Yao; Jeremy O'Sullivan; Ryan McBride; Yadong Wei; Steve M Fernandes; Zhou Zhu; Ronald L Schnaar; Bruce S Bochner; James C Paulson
Journal:  J Am Chem Soc       Date:  2019-08-30       Impact factor: 15.419

Review 9.  Eosinophil and mast cell Siglecs: From biology to drug target.

Authors:  Jeremy A O'Sullivan; Alan T Chang; Bradford A Youngblood; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-01-22       Impact factor: 4.962

10.  An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells.

Authors:  Sheena C Kerr; Jeanmarie R Gonzalez; Julia Schanin; Michael C Peters; Bart N Lambrecht; Emily C Brock; Annabelle Charbit; K M Ansel; Bradford A Youngblood; John V Fahy
Journal:  Clin Exp Allergy       Date:  2020-07-08       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.